



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/048,146	01/25/2002	Victor C.W. Tsang	6395-62068	8734

24197 7590 08/12/2003

KLARQUIST SPARKMAN, LLP
121 SW SALMON STREET
SUITE 1600
PORTLAND, OR 97204

EXAMINER

DEVI, SARVAMANGALA J N

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 08/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/048,146

Applicant(s)

Victor et al.

Examiner

S. Devi, Ph.D.

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on May 27, 2003
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claims 1-16 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 6) ☐ Other: _____

Lack of Unity of Invention(s)

- 1) Claims 1-16 are under prosecution.
- 2) **Please Note:** In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your election responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula.Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 3) The instant inventions lack unity under PCT Rule 13.1 and 13.2:
 - I. Claims 2, 3 and 5, drawn to a composition comprising the TS-14 polypeptide of *T. solium* or antigenic fragments thereof.
 - II. Claims 2, 3 and 5, drawn to a composition comprising the TS-18 polypeptide of *T. solium* or antigenic fragments thereof.
 - III. Claims 2, 3 and 5, drawn to a composition comprising the TSRS-1 polypeptide of *T. solium* or antigenic fragments thereof.
 - IV. Claim 4, drawn to a polypeptide containing SEQ ID NO:7.
 - V. Claims 6 and 7, drawn to a nucleic acid molecule encoding the *T. solium* polypeptide of SEQ ID NO: 2.
 - VI. Claims 6 and 7, drawn to a nucleic acid molecule encoding the *T. solium* polypeptide of SEQ ID NO: 4.
 - VII. Claims 6 and 7, drawn to a nucleic acid molecule encoding the *T. solium* polypeptide of SEQ ID NO: 6.
 - VIII. Claims 9, 10 and 12, drawn to a method of detecting *T. solium* antibodies in a sample using the TS-14 polypeptide of *T. solium* or antigenic fragments thereof.
 - IX. Claims 9, 10 and 12, drawn to a method of detecting *T. solium* antibodies in a sample using the TS-18 polypeptide of *T. solium* or antigenic fragments thereof and detecting the antibody-polypeptide complex.

- X. Claims 9, 10 and 12, drawn to a method of detecting *T. solium* antibodies in a sample using the TSRS-1 polypeptide of *T. solium* or antigenic fragments thereof.
- XI. Claim 11, drawn a method of detecting *T. solium* antibodies in a sample using a polypeptide of SEQ ID NO: 7 and detecting the antibody-polypeptide complex.
- XII. Claims 14 and 16, drawn to a method of diagnosing cysticercosis using the polypeptide of SEQ ID NO: 2 and detecting the antibody-glycoprotein binding.
- XIII. Claims 14 and 16, drawn to a method of diagnosing cysticercosis using the polypeptide of SEQ ID NO: 4 and detecting the antibody-glycoprotein binding.
- XIV. Claims 14 and 16, drawn to a method of diagnosing cysticercosis using the polypeptide of SEQ ID NO: 6 and detecting the antibody-glycoprotein binding.
- XV. Claim 15, drawn to a method of diagnosing cysticercosis using the polypeptide of SEQ ID NO: 7 and detecting the antibody-glycoprotein binding.

Claim 1 is a linking claim and would be joined with one of inventions I-IV, if elected.

Claim 8 is a linking claim and would be joined with one of inventions VIII-XI, if elected.

Claim 13 is a linking claim and would be joined with one of inventions XII-XV, if elected.

4) Inventions I through XV lack unity of inventions due to the absence of a special technical feature. The polypeptide or an antigenic fragment thereof claimed in claim 1, for example, is the special technical feature unifying inventions I-IV in the instant application. However, such a polypeptide antigenic fragment was already disclosed in the art at the time of the invention. For example, Ryan *et al.* (*Mol. Biochem. Parasitol.* 99: 257-261, 30 April 199 - already of record) taught the IAQLAK antigenic fragment (see Table 1). Therefore, the special technical feature does not define over the prior art. It is further noted that, technically, the absence of a special technical feature would permit the separation of the methods of using the products (inventions VIII-XV) from the products themselves. The special technical features of inventions IV-VI are the above-identified three nucleic acid molecules respectively which do not share a significant common structure. The nucleic acids of inventions IV-VI are not required for the methods of inventions VIII through XV.

Applicants are advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. 1.143).

Serial No. 10/048,146
Art Unit: 1645

5) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (703) 308-9347. A telephone message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m. except one day each bi-week, which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

August, 2003


S. DEVI, PH.D.
PRIMARY EXAMINER